The second NMA did not report the definition used; instead, the eligibility criteria were defined in terms of the treatments assessed in the randomized controlled trials (RCTs). The eligibility criteria adopted in each RCT and the resulting patient population characteristics were collected in order to assess comparability among the trials in each NMA. Results: The RCTs selected in each of the NMAs adopted diverse eligibility criteria based on body surface area (BSA), psoriasis area and severity index (PASI) score and exposure or failure to previous therapies. Although many of the trials adopted eligibility criteria that aligned with clinical guideline definitions of moderate to severe PsO as BSA above 10% and PASI above 10, the resulting 'moderate to severe' populations showed wide variation in their baseline characteristics. Analogous differences in placebo responses were observed. For example, baseline PASI scores ranged from 14 to 23, while the proportion of patients with a 75% reduction in the PASI scores at 12 weeks varied from 2% to 18% among the trials in each NMA. ConClusions: The current definitions of 'moderate to severe' PsO do not seem enough to guarantee similarity in severity across trials, which may lead to imbalance in the distribution of potential effect modifiers across comparisons, and consequent bias in the NMA estimates. In the absence of better characterization of the patient population, adjusting for baseline risk is advisable. objeCtives: Children undergoing surgery often experience anxiety, exhibit negative behaviors and suffer postoperative pain. Previous studies showed inconsistent findings in the effects of therapeutic play intervention on children's perioperative anxiety, negative behaviors and postoperative pain. This study aimed to examine the effectiveness of a therapeutic play intervention on perioperative anxiety, negative emotional manifestation and postoperative pain in children undergoing inpatient elective surgery. Methods: A randomized controlled trial with twogroup pre-and post-tests study design was conducted. A total of 106 eligible children (6-14 years old) were recruited and randomly allocated to either a control group (receiving routine care) (n = 53) or an experimental group (receiving onehour therapeutic play intervention in addition to routine care) (n = 53). Outcome measures included children's anxiety, emotional manifestation and postoperative pain which were conducted at baseline (3-7 days before the operation), on the day of surgery, and around 24 hours after surgery. Repeated measures ANCOVA and univariate analysis of covariance were used to analyse the data. Results: Children in the experimental group demonstrated no superior result in perioperative anxiety (p > 0.05), but indicated significantly fewer negative emotional manifestations (p < 0.01) and less postoperative pain (p < 0.01) as compared with those in the control group. ConClusions: The therapeutic play intervention is superior to usual care in reducing negative behaviors and postoperative pain in children undergoing inpatient elective surgery. These findings suggest the need of providing the therapeutic play intervention for school-aged children who are undergoing inpatient elective surgery.
objeCtives: Chronic low back pain (CLBP) with or without radiculopathy is a major expensive, and disabling condition around the globe. Limited safety and efficacy data of various analgesics make difficult in prescribing. Present study aimed at assessing the efficacy and safety of combination therapy of pregabalin and amitriptyline in patients with CLBP in Indian population. Methods: A longitudinal prospective observational study was conducted at pain clinic of a public tertiary care hospital. Adult patients suffering from low back pain for > 3 months, and who received pregabalin (75-150 mg/day) and amitriptyline (10/25 mg/day) were included in the study. Data collected for baseline and follow-ups of monthly through hospital visits and telephonic contacting until 6 months for VAS; baseline and 6 months for Modified Ostwery low back pain Disability questionnaire (MODQ). Percentage of patients achieved > 50% of pain reduction by VAS score (0-100) after six months is the primary endpoint. Safety and improvement in quality of life after six months assessed as secondary endpoint. Analysis done by one way repeated measures anova. Results: A total of 198 patients were included in this study with mean age of 44.8+12.4 years, 63% are having BMI > 25kg/m 2 , and duration of pain 30 (12-60) months. Magnetic imaging resonance findings have shown disc bulging (43.9%), disc herniation (12.6%), spondylosis (11.1%) and other problems. Significant reduction in pain was observed p< 0.01 on VAS score after 6 months follow up. VAS&MODQ baseline median (IQR) scores found to be 75(60-90)&52(40-60), and after 6 months 35(20-50)&41(24-53), no improvement in quality of life found p= 0.08. Dry mouth is being the commonest adverse event [in 80 (40.4) ]. Other adverse events reported are headache, constipation, dizziness and postural hypotension. ConClusions: Our results suggest that combination of pregabalin and amitriptyline are efficacious and safe in managing CLBP. objeCtives: Obesity is a major health crisis with vast economic and populationhealth implications. Effective pharmacological therapies for weight management are desirable, yet few have been approved by the Food and Drug Administration (FDA) since the withdrawal of fenfluramine/phentermine in the late 1990's. Recently a new product, combination phentermine/topiramate, obtained marketing approval. Both phentermine monotherapy and topiramate monotherapy were previously investigated for weight loss, yet only one study compared this new combination product to its respective components. The goal of this current meta-analysis was to compare the effectiveness of phentermine monotherapy, topiramate monotherapy, and phentermine/topiramate combination therapy in weight reduction treatment. Methods: Studies were identified from published meta-analyses, pharmacological weight loss review articles, and electronic databases including PubMED and ClinicalTrials.gov. Eligible studies were randomized placebo-controlled trials with the objective of weight loss assessment. Data from 6 studies of combination phentermine/topiramate, 10 studies of topiramate monotherapy, and 9 studies of phentermine monotherapy were included for analysis. Pooled analysis of mean percent weight change was performed using a random effects model. Intervention-induced weight loss was assessed and described overall and in relation to pooled weight loss estimates of subjects receiving control (placebo) treatment. Results: Phentermine/topiramate combination therapy had a mean percent weight loss above placebo of 7.18% (95% CI -8.22 to -6.14%), a treatment effect larger than the mean percent weight loss above placebo of 4.57% (95% CI -5.39 to -3.76%) calculated for topiramate monotherapy or the mean percent weight loss above placebo of 5.79% (95% CI -6.82 to -4.75%) calculated for phentermine monotherapy. ConClusions: Pooled clinical trial data show that phentermine/topiramate combination therapy is more effective than topiramate monotherapy and phentermine monotherapy in reducing weight. Future studies to assess the effectiveness of phentermine/topiramate combination therapy are merited to determine if these controlled trial-derived weight loss results translate to real-world clinical success. objeCtives: Pain is an important driver of quality of life and health care resource use, though few treatments are available to effectively treat neuropathic pain. The purpose of this study was to characterise the retreatment interval, patch usage and clinical effectiveness of the capsaicin 8% patch 'Qutenza' (QTZ) when used to treat peripheral neuropathic pain in clinical practice. Methods: Interim data were available from a prospective, observational study of people with neuropathic pain treated with QTZ throughout Europe (n= 340); the ASCEND study. The Numeric Pain Rating Scale (NPRS) recorded pain on an integer scale between 0 (no pain) and 10 (worst imaginable pain). Time to retreatment was evaluated using the Kaplan-Meier method, accounting for right-censored observations. Change in pain severity was evaluated using independent sample and paired samples t-tests. Results: At baseline, the mean NPRS was 6.82 (SD 1.89). At eight weeks following first treatment, 43.8% of patients achieved a 30% reduction and 24.2% a 50% reduction. In this analysis, 105 (30.9%) patients were retreated with QTZ at least once, of which 26 (7.7%) had two re-treatments, and 5 (1.5%) had three or more re-treatments. There was no difference in baseline NPRS between those that progressed to receiving multiple treatments and those treated once (mean NPRS= 6.87 vs. 6.67 units respectively (p= 0.355)). Mean NPRS prior to the second application was 5.66 (2.09; p< 0.001), and 5.19 (2.38; p= 0.010) prior to subsequent applications. The mean number of patches used at the first, second and third applications was 1.18 (0.81), 1.16 (0.75) , and 1.19 (1.07), respectively (p= 0.115, p= 0.214). The median time from first to second treatment was 22 weeks (95% CI 17-27), and from second to third a further 21 weeks (95% CI [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . ConClusions: This study shows that capsaicin 8% patch use and retreatment intervals are stable across successive treatments suggesting consistent efficacy.
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PSY4
PSY5 cOmPArAbiliTY Of TriAl POPulATiOnS in neTWOrk meTA-AnAlYSeS ASSeSSing biOlOgic TreATmenTS in mOderATe TO Severe PlAQue PSOriASiS
Smiechowski B, Chen M, Vieira MC Mapi, Boston, MA, USA objeCtives: To assess the comparability of the trials included in network metaanalyses (NMAs) comparing biologic treatments in moderate to severe plaque psoriasis (PsO). Methods: A systematic literature review identified two recently published NMAs. The definition of 'moderate to severe' psoriasis adopted by one of the NMAs was "having an inadequate response to topical treatments alone and either having received prior systemic therapy or being candidate for such therapy". acute care utilization in MF TD patients. Potential short term and long term benefits of ICT in MF need to be validated in prospective clinical trials. objeCtives: Gaucher disease (GD) is a rare genetic disorder characterized by the accumulation of lipid glucosylceramide in organs such as the spleen, liver and bone marrow. Based operationally on the presence and severity of central nervous system manifestations, GD is classified into three types (GD1, GD2, and GD3), although GD1 is the predominant type diagnosed in most regions. However, the epidemiology of GD is not well established. Methods: A comprehensive review of English language literature primarily focusing on the incidence and prevalence of GD was performed. Literature indexed in MEDLINE, EMBASE, and CENTRAL and published between January 1990 and February 2013 was searched. "Grey literature" sources from key congresses were also searched. Results: 22 studies of the epidemiology of GD from North America, Europe, Israel, Australia, and Japan were identified. Nine studies estimated prevalence of GD in the general population at 0.33-1.75 per 100,000. The prevalence was higher in populations of Ashkenazi Jewish descent, ranging from 82.8-222.2 per 100,000. Seven studies reported GD incidence using a general population, while one study screened Ashkenazi Jews to identify carrier couples of GD mutations in Israel. The incidence of GD varied among studies performed in the general population from 0.30-5.80 per 100,000. The highest incidence rate was reported in Austria, where newborns were prospectively screened for mutations in the cognate GBA1 gene, thus likely increasing the cases diagnosed in this population. The estimated carrier frequency of four GBA mutations among individuals of Ashkenazi Jewish descent was 5.7%, and the frequency of affected fetuses in carrier couples who underwent prenatal diagnosis was 23.5%. ConClusions: GD is a rare disorder that disproportionately affects individuals of Ashkenazi Jewish descent. The observed variability of GD incidence and prevalence may be explained by differences in the studied population, region, study design, and diagnostic criteria. objeCtives: To estimate the safety and tolerability of azacitidine in those suffering from intermediate-2 and high risk Myelodysplastic Syndromes (MDS), in a real world setting in Greece. Methods: A nationwide, retrospective chart review study was conducted, based on 17 Hematology departments of Hospitals throughout the country. Eligible patients were analyzed concerning the frequency of Serious and Non-Serious-Adverse Drug Reactions (SADRs/NSADRs). By definition, a SADR could result death, life-threatening condition, significant disability, requires hospitalization or might be considered medically important. Any reaction which does not fulfill the above description is a NSADR. Patients were recruited if were > 18 years and were alive at the time of their data collection, they have completed at least one evaluation after azacitidine treatment initiation and at least one cycle of azacitidine treatment regardless of the outcome. The study was conducted in accordance with the declaration of Helsinki. Results: The incidence of NSADRs and SADR during treatment was 50% and 42%, respectively. The most commonly reported NSADRs were neutropenia (11.4%), thrombocytopenia (9.1%), pyrexia (8.0%) and constipation (8.0%). Regarding their intensity, 45.7% of NSADRs were grade I, 43.6% were grade II, and 10.6% were grade III. None of the NSADRs resulted in patient hospitalization. The most commonly reported SADRs were thrombocytopenia (13.6%), pyrexia (10.2%), neutropenia (9.1%), febrile neutropenia (4.5%), anaemia and respiratory tract infection (both 4.5%). 48.6% of all SADRs were grade III,while 18% were grade IV. In 20.8% of SARDs no action was taken, 1.4% resulted in permanent discontinuation, while temporary treatment interruption was required for 34.7% of patients. 30.7% of patients experienced any SADRs, required hospitalization. ConClusions: In this study, the safety and tolerability of azacitidine for intermediate-2 and high risk MDS patients was descriptively analyzed based on Greek data. A broader, real life, analysis is needed to reach more decisive conclusions in the local setting.
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PSY13
increASing bAriATric PrOcedure vOlume in briTiSh cOlumbiA, cAnAdAA budgeT imPAcT AnAlYSiS Over 10 YeArS Goldstein LJ Johnson & Johnson Medical Companies, Markham, ON, Canada objeCtives: British Columbia (BC) currently performs around 250 bariatric procedures annually. The number of individuals eligible for bariatric surgery in BC is approximately 87,000 and is increasing at about 1.04% annually. Obese individuals are high volume users of the health care system and bariatric surgery has proven to be an effective intervention for weight loss and for reducing the impact of obesityrelated disease. The objective of this study was to determine the budget impact of increasing the volume of bariatric procedures performed in BC to include 1% of all eligible patients each year. Methods: A budget impact model accounting only for direct health care costs was created using data from Statistics Canada, peerreviewed literature, the Canadian Institute for Health Information and case-costing objeCtives: Immune (idiopathic) thrombocytopenia (ITP) is an autoimmune condition characterized by increased platelet destruction and suboptimal platelet production, resulting in low platelet counts (thrombocytopenia). Romiplostim has shown efficacy in increasing platelet counts. The objective of this study was to conduct meta-analysis and present total evidence for Romiplostim for treatment of ITP. Methods: For this meta-analysis we included randomized controlled trials (RCTs) evaluating Romiplostim for the treatment of ITP. We included RCTs that compared romiplostim versus placebo for management of ITP, had a treatment duration of at least 24 weeks, were doubleblind (patients and investigators blinded) and reported data on platelet response. A systematic literature search for Etanercept trials was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was collected for the study size, interventions, year, and the two outcomes overall and durable platelet response rate. For meta-analysis, random effects and fixed effects models were used to obtain cumulative statistics. Results: Two RCTs with a total of 125 patients were identified. The pooled response rates for Romiplostim for overall platelet response rate were 82% (95% CI 73%-90%); and for durable platelet response rate were 48% (95% CI 26%-71%). The pooled response rates for placebo for overall platelet response rate were 7% (95% CI 0%-15%), and for durable platelet response rate were 2% (95% CI 0%-4%). For overall platelet response rate the cumulative relative risk with placebo versus Romiplostim was 0.09 (95% CI 4%-14%). For durable platelet response rate, the cumulative relative risk with placebo versus Romiplostim was 0.03 (95% CI 0%-6%). ConClusions: Meta-analysis shows Romiplostim offers patients with Immune idiopathic thrombocytopenia an effective therapeutic option for increasing platelet counts. objeCtives: Obinutuzumab (GA101) is a novel, glycoengineered, type II CD20 antibody. In the phase 3 CLL11 trial, chlorambucil (Clb) plus GA101 (G-Clb) significantly prolonged progression-free survival (PFS) compared with either Clb alone or rituximab plus Clb in previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities. We present indirect treatment comparisons (ITCs) of G-Clb versus bendamustine (Benda), and ofatumumab plus Clb (Ofat-Clb). Methods: We conducted a systematic review of non-randomized and randomized controlled trials (RCTs) to assess the clinical efficacy and safety of pharmacological interventions for previously untreated CLL; manuscripts (Jan 1992 to Mar 2013), abstracts (including hand-searching; Jan 2010 to Mar 2013), and in-progress trials were screened for inclusion. Based on extracted data, a feasibility assessment of quantitative analysis was undertaken. ITCs of G-Clb versus Benda and G-Clb versus Ofat-Clb were derived. The WinBUGS code used to parameterize the fixed-effect network meta-analysis model used a natural logarithm of the hazard ratios (HR) for PFS as the (continuous) outcome variable. Results: Of the 4,819 publications identified, 262 manuscripts and 13 abstracts were selected for detailed evaluation. Following de-duplication of publications, the data set included 28 RCTs (157 publications) and nine non-RCTs (14 publications). ITCs were based on HR and 95% confidence intervals (CIs) reported for G-Clb in the CLL11 trial, for Benda in the Knauf et al. publications, and for OfatClb in the Complement 1 trial. The ITC for G-Clb versus Benda had a HR (95% CI) of 0.53 (0.35-0.77) and the ITC for G-Clb versus Ofat-Clb had a HR (95% CI) of 0.33 (0.22-0.47). ConClusions: Based on the ITCs of available evidence in this indication, G-Clb is expected to improve PFS rates compared with Benda or Ofat-Clb. How this benefit will translate into overall survival differences will be assessed when the available data are more mature.
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